Cadila Pharma inaugurates Greenfield API manufacturing plant at Dahej

Published On 2023-11-30 04:30 GMT   |   Update On 2023-11-30 12:23 GMT
Advertisement

Dahej: Cadila Pharmaceuticals, one of the oldest and largest privately-held drug manufacturers in the country, inaugurated its Greenfield Active Pharmaceutical Ingredients (API) manufacturing plant at Dahej in Bharuch district.

Set up with an investment of Rs. 200 crore, the state-of-the-art facility is equipped with the latest Distributed Control System (DCS) automation technology.
Dr. HG Koshia, Commissioner of Food and Drugs Control Administration (FDCA), Gujarat, and Dr. MP Nakrani, Assistant Commissioner of FDCA, Bharuch Circle, graced the inauguration ceremony with their presence.
Advertisement
Dr. Koshia said, “It is truly a pleasure to visit Cadila Pharmaceuticals’ state-of-the-art API project at Dahej. It is a great moment for me, and my tribute to the legendary Pharma Man of India and catalyst of the Gujarat Pharma industry, Late Shri IA Modi. I feel and sense his presence by visiting such a beautiful creation. We miss his presence, but under his guidance and able leadership, Cadila Pharmaceuticals has created a unique API plant that will serve humankind for many years by producing quality APIs.”
Speaking on the occasion, Biswajit Mitra, Chief Mentoring Officer at Cadila Pharmaceuticals, said, “This state-of-the-art API manufacturing facility at Dahej represents our commitment to providing high-quality, cost-effective APIs to our customers worldwide. The DCS technology used in this facility will allow us to produce APIs with a high level of purity and consistency, while also reducing the environmental impact. This facility is designed to be highly efficient, aiding us in meeting the growing demand for our products. I am confident this facility will play a key role in our future success.”
Cadila Pharmaceuticals had earlier signed an MoU with the government of Gujarat for investing Rs. 1,000 crore in Gujarat. The Dahej API facility is one of the projects for which the MoU was signed.
The new API manufacturing facility will enable Cadila Pharmaceuticals to provide customers with quality products, while also helping it to expand its reach into new markets.
The facility incorporates advanced Distributed Control System technology, enhancing greater precision and efficiency in the production process. The facility is designed with a focus on sustainable practices, aligning with Cadila Pharmaceuticals’ broader environmental initiatives and reflects its commitment to advancing healthcare solutions through cutting-edge technology and sustainable practices.
Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News